This story was originally posted on April 20.

Fluidigm made two moves in recent weeks that put its integrated fluidic circuit biochips in direct competition with microarrays sold by vendors like Affymetrix, Agilent Technologies, Illumina, and Roche NimbleGen.

First, the South San Francisco, Calif.-based firm announced the establishment of a subsidiary in Shanghai, allowing it to directly serve customers from the same city in China where competitors like Affy and Illumina have their offices.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.